Results from the phase 3 FOURIER and FOURIER open label extension (OLE) studies of evolocumab (Repatha; Amgen) in adults with atherosclerotic cardiovascular disease (ASCVD) found that achieving and sustaining a low-density lipoprotein cholesterol (LDL-C) level of &LT20 mg/dL led to improved cardiovascular (CV) outcomes. These outcomes include the composite endpoint of cardiovascular death, myocardial infarction (MI), and stroke with no evidence of an increased incidence of safety events for up to 8.6 years of follow-up. "The current analysis further supports that achieving very low LDL-C long-term is not associated with any new safety signals and correlates with the reduction in cardiovascular events in patients with atherosclerotic cardiovascular disease," said David M. Reese, MD, executive vice president of Research and Development at Amgen, in a press release.